Skip to content

Cogent Biosciences, Inc. COGT Free cash flow margin

Discontinued — last reported Q4 '19

Free cash flow margin at other companies

Pfizer logo
PfizerPFE
18%+8.8pp
Amgen logo
AmgenAMGN
23.1%-8.9pp
Incyte logo
IncyteINCY
28.2%+19.7pp
Tango Therapeutics logo
Tango TherapeuticsTNGX
-250.1%-49.4pp
CG Oncology logo
CG OncologyCGON
-3,163.8%-1,351pp
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-1,536%-429pp

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Calculated from Cogent Biosciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Cogent Biosciences, Inc.’s 10-K, filed March 16, 2021, on SEC EDGAR. View the filing →

Questions, answered.

What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.